Faron Pharmaceuticals Ltd has appointed new leadership as the company prepares to advance clinical development of bexmarilimab, its wholly-owned immunotherapy for both haematological and solid tumours. The company’s founder and chief executive officer, Markku Jalkanen, is to retire and be replaced by his son, Juho Jalkanen, currently the chief operating officer. The new CEO will take up his position on 1 May.
Clinical data generated for bexmarilimab in 2023 was positive and a decision was taken to investigate the drug in combination with a standard of care in patients who have failed treatment with a hypomethylating agent and are at a high risk of myelodysplastic syndrome. Bexmarilimab targets myeloid cell function with the goal of activating the immune system. The company said it plans to seek scientific advice from the US Food and Drug Administration about a possible a registrational study for the drug.
Faron announced the appointment on 15 April 2024.
Copyright 2024 Evernow Publishing Ltd.